Jose G. Trevino, Justin M. Summy and Gary E. Gallick Pages 681 - 687 ( 7 )
Selective inhibitors of the Src family of protein tyrosine kinases have been developed as therapeutic agents for human tumors, some of which are now in various stages of clinical trial. In this review, recently described novel small molecule ATP-competitive Src inhibitors are discussed, with an emphasis on their potential use as therapeutic inhibitors for advanced-stage malignancies.
Src family kinase, Inhibitors, Adenocarcinoma
University of Texas MDAnderson Cancer Center, Department of Cancer Biology, Unit 173, SmithResearch Building, 7777 Knight Rd, Houston TX 77054, USA.